Fluvoxamine Does Not Improve Time to Sustained Recovery in Mild COVID-19
THURSDAY, Jan. 12, 2023 (HealthDay News) -- For patients with mild-to-moderate COVID-19, treatment with fluvoxamine does not improve time to sustained recovery versus placebo, according to a study published online Jan. 12 in Journal of the American Medical Association.
Matthew W. McCarthy, M.D., Ph.D., from Weill Cornell Medicine in New York City, and colleagues examined the efficacy of low-dose (50 mg twice daily) fluvoxamine for 10 days versus placebo among 1,288 patients (674 in the fluvoxamine group and 614 in the placebo group) aged 30 years or older with severe acute respiratory syndrome coronavirus 2 infection and experiencing two or more symptoms of acute COVID-19 for seven days or less.
The researchers found that the median time to sustained recovery was 12 and 13 days in the fluvoxamine and placebo groups, respectively (hazard ratio, 0.96; 95 percent credible interval, 0.86 to 1.06). Overall, 3.9 and 3.8 percent of participants in the fluvoxamine and placebo groups, respectively, had the composite outcome of hospitalization, urgent care visit, emergency department visit, or death through day 28 (hazard ratio, 1.1; 95 percent credible interval, 0.5 to 1.8). One and two participants in the fluvoxamine and placebo groups, respectively, were hospitalized; there were no deaths reported in either group.
"These findings do not support the use of fluvoxamine at this dose and duration in patients with mild-to-moderate COVID-19," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Related Posts
Poll Finds Nearly Half of Americans Unprepared for Medical Emergency
FRIDAY, Jan. 20, 2023 (HealthDay News) -- Nearly half of American adults are not...
How Worried Should the World Be About Bird Flu in Humans?
TUESDAY, Feb. 14, 2023 (HealthDay News) -- A highly infectious strain of avian...
AHA News: Susan Lucci’s New Stent and Renewed Mission For Women’s Heart Health
MONDAY, Feb. 14, 2022 (American Heart Association News) -- After years of...
FDA Says ADHD Med Adderall Is in Short Supply
THURSDAY, Oct. 13, 2022 (HealthDay News) -- People with...